Pulmonary Alveolar Proteinosis and new therapeutic concepts

Abstract

Pulmonary alveolar proteinosis (PAP) is an umbrella term used to refer to a pulmonary syndrome which is characterized by excessive accumulation of surfactant in the lungs of affected individuals. In general, PAP is a rare lung disease affecting children and adults, although its prevalence and incidence is variable among different countries. Even though PAP is a rare disease, it is a prime example on how modern medicine can lead to new therapeutic concepts, changing ways and techniques of (genetic) diagnosis which ultimately led into personalized treatments, all dedicated to improve the function of the impaired lung and thus life expectancy and quality of life in PAP patients. In fact, new technologies, such as new sequencing technologies, gene therapy approaches, new kind and sources of stem cells and completely new insights into the ontogeny of immune cells such as macrophages have increased our understanding in the onset and progression of PAP, which have paved the way for novel therapeutic concepts for PAP and beyond. As of today, classical monocyte-derived macrophages are known as important immune mediator and immune sentinels within the innate immunity. Furthermore, macrophages (known as tissue resident macrophages (TRMs)) can also be found in various tissues, introducing e. g. alveolar macrophages in the broncho-alveolar space as crucial cellular determinants in the onset of PAP and other lung disorders. Given recent insights into the onset of alveolar macrophages and knowledge about factors which impede their function, has led to the development of new therapies, which are applied in the context of PAP, with promising implications also for other diseases in which macrophages play an important role. Thus, we here summarize the latest insights into the various forms of PAP and introduce new pre-clinical work which is currently conducted in the framework of PAP, introducing new therapies for children and adults who still suffer from this severe, potentially life-threatening disease.

Zusammenfassung

Pulmonale Alveolar Proteinose (PAP) ist ein Überbegriff für ein pulmonales Syndrom, das durch die übermäßige Akkumulation von Surfactant in den Lungen von betroffenen Patienten gekennzeichnet ist. PAP ist eine seltene Erkrankung, die sowohl Kinder als auch Erwachsene betrifft und deren Prävalenz und Inzidenz stark zwischen verschiedenen Ländern variiert. Obwohl die PAP eine seltene Erkrankung ist, so ist diese Krankheit ein gutes Beispiel wie Fortschritte in der modernen Medizin zu neuen therapeutischen Ansätzen und veränderten Methoden und Techniken in der genetischen Diagnostik führen, welches schlussendlich die Lungenfunktion der Patienten verbessern und somit eine höhere Lebenserwartung und gesteigerte Lebensqualität der Patienten ermöglichen. Zum besseren Verständnis in der Krankheitsentstehung haben aktuelle Technologien wie neuste Genomsequenzierung, moderne Gentherapieansätze, Möglichkeiten der Stammzellgewinnung sowie neuste Erkenntnisse in der Ontogenese von Immunzellen wie beispielsweise Makrophagen, maßgeblich dazu beigetragen die Lebensqualität von Patienten zu verbessern. Damit wurde der Weg für neue therapeutische Ansätze in der Behandlung von PAP geebnet, aber auch ein großer Beitrag zum allgemeinen wissenschaftlichen Verständnis erbracht. Im Bereich der PAP und als wesentliche Grundlage in der Krankheitsentstehung haben sich klassische, aus Monozyten differenzierte Makrophagen als wichtiger Wächter und Modulator der angeborenen Immunabwehr etabliert. Darüber hinaus sind auch gewebespezifische Makrophagen (tissue resident macrophages, TRM) in nahezu allen Geweben, so auch der Lunge, des menschlichen Körpers zu finden und gewinnen im medizinischen Kontext zunehmend an Bedeutung. So spielen beispielsweise die Alveolar-Makrophagen, die im broncho-alveolären Raum angesiedelt sind, eine tragende Rolle in der Pathophysiologie von PAP sowie weiteren Lungenerkrankungen. Nicht nur in der Behandlung von PAP sind daher die neuen Erkenntnisse über die Funktionsweise und mögliche Funktionseinschränkungen der Alveolar-Makrophagen wegweisend für neue Behandlungskonzepte, sondern bieten auch große Chancen für moderne Therapieansätze in der Behandlung von weiteren Krankheiten in denen Makrophagen relevant zur Krankheitsentstehung beitragen. Aus diesem Grund werden in dieser Übersichtsarbeit die neuesten wissenschaftlichen Erkenntnisse über die verschiedenen Formen von PAP sowie aktuelle präklinische Untersuchungen im Kontext von PAP zusammentragen und die neuen Behandlungsmöglichkeiten vorstellen.

Key words

Macrophage - Immunity - Lung - Proteinosis

Schlüsselwörter

Makrophagen - Immunität - Lungenerkrankung - Proteinose

^* Authors contributed equally

Publication History

Received: 02 November 2023
Received: 28 November 2023

Accepted: 15 December 2023

Article published online:
29 January 2024

• References

• 1 Kelly A, McCarthy C. “Pulmonary Alveolar Proteinosis Syndrome,”. Semin Respir Crit Care Med 2020; 41: 288-298
• 2 Veldhuizen R, Nag K, Orgeig S. et al. “The role of lipids in pulmonary surfactant,”. Biochim. Biophys. Acta - Mol. Basis Dis. 1998; 1408: 90-108
• 3 Ikegami M. et al. “Surfactant granulocyte rnetabolism in transgenic mice after stimulating factor ablation,”. Am J Physiol 1996; 270: L650-L658
• 4 Reed JA, Ikegami M, Robb L. et al “Distinct changes in pulmonary surfactant homeostasis in common β-chain- and GM-CSF-deficient mice,”. Am. J. Physiol. - Lung Cell. Mol. Physiol. 2000; 278 22-6 1164-1171
• 5 Inoue Y. et al. “Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan,”. Am. J. Respir. Crit. Care Med. 2008; 177: 752-762
• 6 Seymour JF, Presneill JJ. “Pulmonary alveolar proteinosis: Progress in the first 44 years,”. Am. J. Respir. Crit. Care Med. 2002; 166: 215-235
• 7 McCarthy C, Avetisyan R, Carey BC. et al. “Prevalence and healthcare burden of pulmonary alveolar proteinosis,”. Orphanet J. Rare Dis 2018; 1-5
• 8 Watanabe S, Itoh T, Arai K. “Roles of JAK kinases in human GM-CSF receptor signal transduction,”. J. Allergy Clin. Immunol. 1996; 98 PART 2
• 9 Lehtonen A, Matikainen S, Miettinen M. et al “induced STAT5 activation and target-gene expression during human monocyte/macrophage differentiation,”. J. Leukoc. Biol. 2002; 71 no. March 511-519
• 10 Shibata Y, Berclaz PY, Chroneos ZC. et al. “GM-CSF regulates alveolar macrophage differentiation and innate. immunity in the lung through PU.1,” Immunity 2001; 15: 557-567
• 11 Schneider C, Nobs SP, Kurrer M. et al. “Induction of the nuclear receptor PPAR-γ 3 by the cytokine GM-CSF is critical for the differentiation of fetal monocytes into alveolar macrophages,”. Nat. Immunol. 2014; 15: 1026-1037
• 12 Sallese A. et al. “Targeting cholesterol homeostasis in lung diseases,”. Sci. Rep. 2017; 7: 1-14
• 13 Uchida K. et al. “High-affinity autoantibodies specifically eliminate granulocyte-macrophage colony-stimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis,”. Blood 2004; 103: 1089-1098
• 14 Kitamura T. et al. “Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor,”. J. Exp. Med. 1999; 190: 875-880
• 15 Beccaria M. et al. “Long-term durable benefit after whole lung lavage in pulmonary alveolar proteinosis,”. Eur. Respir. J. 2004; 23: 526-531
• 16 Jehn LB, Bonella F. “Pulmonary alveolar proteinosis - Current and future therapeutical strategies,”. Curr. Opin. Pulm. Med. 2023; 29: 465-474
• 17 Trapnell BC. et al. “Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis,”. N. Engl. J. Med. 2020; 383: 1635-1644
• 18 Tazawa R. et al. “Inhaled GM-CSF for Pulmonary Alveolar Proteinosis,”. N. Engl. J. Med. 2019; 381: 923-932
• 19 Suzuki T. et al. “Hereditary pulmonary alveolar proteinosis caused by recessive CSF2RB mutations,”. Eur. Respir. J. 2011; 37: 201-204
• 20 Griese M. et al. “Autoimmune pulmonary alveolar proteinosis in children,”. ERJ Open Res 2022; 8: 1-7
• 21 Suzuki T. et al. “Hereditary pulmonary alveolar proteinosis: Pathogenesis, presentation, diagnosis, and therapy,”. Am. J. Respir. Crit. Care Med. 2010; 182: 1292-1304
• 22 Martinez-Moczygemba M. et al. “Pulmonary alveolar proteinosis caused by deletion of the GM-CSFRα gene in the X chromosome pseudoautosomal region 1,”. J. Exp. Med. 2008; 205: 2711-2716
• 23 Tanaka T. et al. “Adult-onset hereditary pulmonary alveolar proteinosis caused by a single-base deletion in CSF2RB,”. J. Med. Genet. 2011; 48: 205-209
• 24 Ito M. et al. “Elderly-onset hereditary pulmonary alveolar proteinosis and its cytokine profile,”. BMC Pulm. Med. 2017; 17: 1-7
• 25 Sakagami T. et al. “Patient-derived granulocyte/macrophage colony-stimulating factor autoantibodies reproduce pulmonary alveolar proteinosis in nonhuman primates,”. Am. J. Respir. Crit. Care Med. 2010; 182: 49-61
• 26 Hayashida K, Kitamura T, Gorman DM. et al. “Molecular cloning of a second subunit of the receptor for human granulocyte-macrophage colony-stimulating factor (GM-CSF): Reconstitution of a high-affinity GM-CSF receptor,”. Proc. Natl. Acad. Sci. U. S. A. 1990; 87: 9655-9659
• 27 Chen Y, Li F, Hua M. et al “Role of GM-CSF in lung balance and disease,”. Front. Immunol. 2023; 14 no. April 1-9
• 28 Lachmann N. et al. “Gene correction of human induced pluripotent stem cells repairs the cellular phenotype in pulmonary alveolar proteinosis,”. Am. J. Respir. Crit. Care Med. 2014; 189: 167-182
• 29 Ishii H. et al. “Clinical features of secondary pulmonary alveolar proteinosis: pre-mortem cases in Japan,”. Eur. Respir. J. 2011; 37: 465-468
• 30 Zhang D. et al. “Secondary pulmonary alveolar proteinosis: A single-center retrospective study (a case series and literature review),”. BMC Pulm. Med. 2018; 18: 1-7
• 31 Ladeb S, Fleury-Feith J, Escudier E. et al. “Secondary alveolar proteinosis in cancer patients,”. Support. Care Cancer 1996; 4: 420-426
• 32 Philippot Q. et al. “Secondary pulmonary alveolar proteinosis after lung transplantation: A single-centre series,”. Eur. Respir. J. 2017; 49
• 33 Griese M. et al. “GATA2 deficiency in children and adults with severe pulmonary alveolar proteinosis and hematologic disorders,”. BMC Pulm. Med. 2015; 15: 1-8
• 34 Israel RH, Magnussen CR. “Are AIDS patients at risk for pulmonary alveolar proteinosis?,”. Chest 1989; 96: 641-642
• 35 Patiroglu T, Akyildiz B, Patiroglu TE. et al. “Recurrent pulmonary alveolar proteinosis secondary to agammaglobulinemia,”. Pediatr. Pulmonol. 2008; 43: 710-713
• 36 Cuellar-Rodriguez J. et al. “Nonmyeloablative allogeneic hematopoietic stem cell transplantation for GATA2 deficiency,”. Blood 2011; 118: 3715-3720
• 37 Fukuno K. et al. Successful cord blood transplantation for myelodysplastic syndrome resulting in resolution of pulmonary alveolar proteinosis [4],”. Bone Marrow Transplant. 2006; 38: 581-582
• 38 Numata A. et al. “Successful therapy with whole-lung lavage and autologous peripheral blood stem cell transplantation for pulmonary alveolar proteinosis complicating acute myelogenous leukemia,”. Am. J. Hematol. 2006; 81: 107-109
• 39 Hamvas A. et al. “Heterogeneous pulmonary phenotypes associated with mutations in the thyroid transcription factor gene NKX2-1,”. Chest 2013; 144: 794-804
• 40 Bush A. et al. “European protocols for the diagnosis and initial treatment of interstitial lung disease in children,”. Thorax 2015; 70: 1078-1084
• 41 Campo I. et al. “Assessment and management of pulmonary alveolar proteinosis in a reference center,”. Orphanet J. Rare Dis 2013; 8: 1
• 42 Ben-Abraham R, Greenfeld A, Rozenman J. et al. “Pulmonary alveolar proteinosis: Step-by-step perioperative care of whole lung lavage procedure,”. Hear. Lung J. Acute Crit. Care 2002; 31: 43-49
• 43 Campo I. et al. “Whole lung lavage therapy for pulmonary alveolar proteinosis: A global survey of current practices and procedures,”. Orphanet J. Rare Dis 2016; 11: 1-10
• 44 Griese M. “Pulmonary alveolar proteinosis: A comprehensive clinical perspective,”. Pediatrics 2017;
• 45 Luisetti M, Kadija Z, Mariani F. et al. “Therapy options in pulmonary alveolar proteinosis,”. Ther. Adv. Respir. Dis. 2010; 4: 239-248
• 46 Tagawa T. et al. “Living-donor lobar lung transplantation for pulmonary alveolar proteinosis in an adult: Report of a case,”. Surg. Today 2011; 41: 1142-1144
• 47 Palomar LM, Nogee LM, Sweet SC. et al. “Long-term outcomes after infant lung transplantation for surfactant protein B deficiency related to other causes of respiratory failure,”. J. Pediatr. 2006; 149: 548-553
• 48 Takaki M. et al. “Recurrence of pulmonary alveolar proteinosis after bilateral lung transplantation in a patient with a nonsense mutation in CSF2RB,”. Respir. Med. Case Reports 2016; 19: 89-93
• 49 Santamaria F. et al. “Recurrent fatal pulmonary alveolar proteinosis after heart-lung transplantation in a child with lysinuric protein intolerance,”. J. Pediatr. 2004; 145: 268-272
• 50 Nishinakamura R. et al. “The pulmonary alveolar proteinosis in granulocyte macrophage colony-stimulating factor/interleukins 3/5 βc receptor-deficient mice is reversed by bone marrow transplantation,” . J. Exp. Med. 1996; 183: 2657-2662
• 51 Kleff V. et al. “Gene therapy of βc-deficient pulmonary alveolar proteinosis (βc-PAP): Studies in a murine in vivo model,”. Mol. Ther. 2008; 16: 757-764
• 52 Frémond ML. et al. “Successful haematopoietic stem cell transplantation in a case of pulmonary alveolar proteinosis due to GM-CSF receptor deficiency,”. Thorax 2018; 73: 590-592
• 53 Tabata S. et al. “Successful allogeneic bone marrow transplantation for myelodysplastic syndrome complicated by severe pulmonary alveolar proteinosis,”. Int. J. Hematol. 2009; 90: 407-412
• 54 Pidala J, Khalil F, Fernandez H. “Pulmonary alveolar proteinosis following allogeneic hematopoietic cell transplantation,”. Bone Marrow Transplant 2011; 46: 1480-1483
• 55 Suzuki T. et al. “Use of induced pluripotent stem cells to recapitulate pulmonary alveolar proteinosis pathogenesis,”. Am. J. Respir. Crit. Care Med. 2014; 189: 183-193
• 56 Mucci A. et al. “iPSC-Derived Macrophages Effectively Treat Pulmonary Alveolar Proteinosis in Csf2rb-Deficient Mice,”. Stem Cell Reports 2018; 11: 696-710
• 57 Happle C. et al. “Pulmonary transplantation of human induced pluripotent stem cell-derived macrophages ameliorates pulmonary alveolar proteinosis,”. Am. J. Respir. Crit. Care Med. 2018; 198: 350-360
• 58 Shi S. et al. “Assessment of Statin Treatment for Pulmonary Alveolar Proteinosis without Hypercholesterolemia: A 12-Month Prospective, Longitudinal, and Observational Study,”. Biomed Res. Int. 2022; 2022
• 59 McCarthy C. et al. “Statin as a novel pharmacotherapy of pulmonary alveolar proteinosis,”. Nat. Commun. 2018; 9: 1-9
• 60 Ozcelik U. et al. “Nonmyeloablative hematopoietic stem cell transplantation in a patient with hereditary pulmonary alveolar proteinosis,”. Pediatr. Pulmonol. 2021; 56: 341-343
• 61 Beeckmans H. et al “Allogeneic Hematopoietic Stem Cell Transplantation After Prior Lung Transplantation for Hereditary Pulmonary Alveolar Proteinosis: A Case Report,”. Front. Immunol. 2022; 13 no 1-9
• 62 Hetzel M. et al. “Effective hematopoietic stem cell-based gene therapy in a murine model of hereditary pulmonary alveolar proteinosis,”. Haematologica 2020; 105: 1147-1157
• 63 Schneider C. et al. “Alveolar Macrophages Are Essential for Protection from Respiratory Failure and Associated Morbidity following Influenza Virus Infection,”. PLoS Pathog 2014; 10
• 64 Happle C. et al. “Pulmonary transplantation of macrophage progenitors as effective and long-lasting therapy for hereditary pulmonary alveolar proteinosis,”. Sci. Transl. Med. 2014; 6
• 65 Suzuki T. et al. “Pulmonary macrophage transplantation therapy,”. Nature 2014; 514: 450-454
• 66 Ackermann M. et al. “Bioreactor-based mass production of human iPSC-derived macrophages enables immunotherapies against bacterial airway infections,”. Nat. Commun. 2018; 9
• 67 Ackermann M. et al. “Continuous human iPSC-macrophage mass production by suspension culture in stirred tank bioreactors,”. Nat. Protoc. 2022; 17: 513-539
• 68 Hetzel M. et al. “Function and Safety of Lentivirus-Mediated Gene Transfer for CSF2RA-Deficiency,”. Hum. Gene Ther. Methods 2017; 28: 318-329
• 69 Arumugam P. et al. “Long-Term Safety and Efficacy of Gene-Pulmonary Macrophage Transplantation Therapy of PAP in Csf2ra−/− Mice,”. Mol. Ther. 2019; 27: 1597-1611